Format

Send to

Choose Destination
Cancer Invest. 2017 Mar 16;35(3):187-194. doi: 10.1080/07357907.2016.1276185. Epub 2017 Feb 6.

Targeting VEGFR-2 in Metastatic Gastric Cancer: Results From a Literature-Based Meta-Analysis.

Author information

1
a Department of Oncology , Medical Oncology Unit, San Donato Hospital , Arezzo , Italy.
2
b Unit of Molecular Therapy and Pharmacogenomic, ASST Cremona , Cremona , Italy.
3
c Department of Medical , Surgery and Health Sciences, University of Trieste , Trieste , Italy.
4
d Unit of General and Minimally Invasive Surgery, Surgery and Neuroscience ; University of Siena , Siena , Italy.
5
e Medical Oncology Unit , University of Siena , Siena , Italy.
6
f Unit of General Medicine , AziendaOspedaliera "C. Poma" Presidio Ospedaliero di Pieve di Coriano , Mantova , Italy.
7
g Unit of Radiotherapy, Department of Medical , Surgical Sciences and Neurosciences, Siena University , Siena , Italy.

Abstract

Angiogenesis is a key process in cancer development. We performed a meta-analysis to assess the efficacy and safety of the novel VEGFR-2 inhibitors in patients with metastatic gastric and gastroesophageal junction cancer. A literature-based meta-analysis of randomized controlled trials (RCTs) was undertaken. The primary outcome was the overall survival. The pooled analysis from RCTs on anti-VEGFR-2 inhibitors revealed a significant increase in overall survival (hazard ratio for death: 0.69, 95% confidence interval: 0.55-0.87; p = .002). This study confirms the efficacy of novel anti-VEGFR-2 inhibitors. The future studies of these agents will evaluate alone and in combination with chemotherapy the early line of treatment along with the identification of proper predictive biomarker.

KEYWORDS:

VEGFR-2; angiogenesis; apatinib; ramucirumab

PMID:
28165839
DOI:
10.1080/07357907.2016.1276185
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center